Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a psychiatric biomarker strategy to support its clinical trials.

Abide's shareholders will receive $250 million up front and are eligible for $150 million in milestones.

Launched in 2011

Read the full 612 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE